Cytosorbents Corp (CTSO) stock
Close on Nov 13, 2026Market cap $306.04MP/E –Yield –
Cytosorbents Corp grew revenue 3.1% to $37.22M over the twelve months to Jun 30, 2026. Free cash flow was -$9.30M. At the latest close the market valued the company at $306.04M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $306.04M
- P/E ratio
- –
- Price to sales
- 8.22
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -3.04%
Fundamentals
- Revenue
- $37.22M
- Net income
- -$18.21M
- EPS, diluted
- -$0.29
- Free cash flow
- -$9.30M
- Book value per share
- -$0.01
- Diluted shares
- 63M
Trading
- Next earnings
- Mar 24, 2027 (estimated, during market hours)
- Previous close
- $5.37
- Open
- $5.79
- Day's range
- $4.78 – $5.87
- Volume
- 10,998
- Average volume (20 days)
- 43,306
- Beta (5 years)
- 0.94
- 52-week range
- $2.84 – $17.00
- RSI (14 days)
- 49.5
- Volatility (1 year)
- 99.8%
- Relative volume
- 0.41×
- WACC
- 9.6%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CTSO | S&P 500 | Difference | CTSO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +40.8% | -3.0% | +43.8 pts | ||
| 3 months | -32.8% | -2.8% | −30.0 pts | ||
| Year to date | -61.9% | +11.5% | −73.4 pts | ||
| 1 year | -63.4% | +13.5% | −76.9 pts | ||
| 3 years | -81.1% | +77.7% | −158.8 pts | -42.6% | +21.1% |
| 5 years | -96.1% | +72.6% | −168.7 pts | -47.8% | +11.5% |
| 10 years | -95.6% | +308.2% | −403.7 pts | -26.8% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cytosorbents filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
About Cytosorbents
Surgical & Medical Instruments & Apparatus
CytoSorbents Corporation develops and commercializes blood purification technologies designed to treat life-threatening conditions in intensive care units and cardiac surgery. Its core platform utilizes porous polymer beads inside cartridges to capture and filter toxic substances, cytokines, and drugs from blood and bodily fluids. The company’s commercial offerings include CytoSorb, an extracorporeal cytokine adsorber for critical illness and cardiac surgery; ECOS-300CY, an ex vivo organ perfusion cartridge for transplant preservation; VetResQ for animal emergency care; and the PuriFi hemoperfusion pump. The firm also develops the investigational DrugSorb-ATR system for antithrombotic removal. CytoSorbents serves hospitals, critical care facilities, and veterinary practices.
Company profile, executives and historyCytosorbents stock: common questions
What is Cytosorbents's stock price?
CTSO closed at $4.87 on Nov 13, 2026, down 9.31% on the day. Over the past 52 weeks it traded between $2.84 and $17.00.
What is Cytosorbents's market cap?
Cytosorbents was worth $306.04M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is CTSO's P/E ratio?
Cytosorbents lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.29), so it has no meaningful P/E ratio.
How much revenue does Cytosorbents make?
Cytosorbents reported revenue of $37.22M for the twelve months to Jun 30, 2026, up 3.1% from a year earlier.
Does Cytosorbents pay a dividend?
No. Cytosorbents has not paid a cash dividend over the last twelve months.
When does Cytosorbents report earnings next?
Cytosorbents is expected to report Q4 FY2026 results on Mar 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CTSO stock performed over the past year?
Including dividends, CTSO returned -63.4% over the past year, against +13.5% for the S&P 500.
How many CTSO shares are sold short?
0M shares were sold short at the latest FINRA report, 0.22% of the float, or 1.1 days of average trading volume.
Who are Cytosorbents's competitors?
Companies most similar to Cytosorbents by business, industry and size include KRMD, NEPH, CLPT, OBIO, UTMD.
See a number that looks wrong?